Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
Dateline City:
KENILWORTH, N.J.
New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma
Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new study findings investigating the use of KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, across a range of
hematological cancers were presented at the 57th American
Society of Hematology (ASH) Annual Meeting.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK ASH cancer Keytruda NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lymphoma | Merck | Myeloma | Pharmaceuticals | Study